Author | Erica DiNapoli | OncLive

Author | Erica DiNapoli


Atezolizumab/Radium-223 Combo Shows No Benefit in mCRPC, But Biomarker Work Planned

June 29, 2020


Michael J. Morris, MD, discusses the combination of atezolizumab and radium-223 dichloride, which did not demonstrate a clinical benefit in patients with metastatic castration-resistant prostate cancer.

Systematic Germline Genetic Testing Is Feasible in Veterans With Metastatic Prostate Cancer

June 29, 2020


Alexandra Sokolova, MD, discusses the implementation of systematic germline genetic testing in veterans with metastatic prostate cancer appeared to be feasible due to high consent rates, especially with direct oncologist involvement.

Pembrolizumab Continues to Show Modest Clinical Activity in Advanced Ovarian Cancer

June 23, 2020


Pembrolizumab demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer.

Saad Highlights Striking Survival Benefit With Apalutamide in nmCRPC

June 22, 2020


The addition of apalutamide to androgen deprivation therapy, significantly improved overall survival and metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer.